Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 5, 2003, Pages 362-367

  Patiño García, Ana ^a,c   Sotillo Piñeiro, Elena ^a   Zalacaín Díez, Marta ^a   Gárate Iturriagagoitia, Leire ^a   Antillón Klüssmann, Federico ^b   Sierrasesúmaga Ariznabarreta, Luis ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b National Pediatric Oncology Unit   (Guatemala)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Loss of heterozygosity; Methylation; Mutation; Survival; Tumor suppressor gene

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DNA DAMAGE; FEMALE; GENE MUTATION; GENETIC REGULATION; HETEROZYGOSITY LOSS; HUMAN; MALE; METHYLATION; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADOLESCENT; ADULT; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM METASTASIS; OSTEOSARCOMA; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038221272     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200305000-00003     Document Type: Article

References (26)

1. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-31.
2. Tsuchiya T, Sekine K, Hinohara S, et al. Analysis of the p16INK4, p14ARF, p15, TP53 and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000;120:91-8.
3. Wunder JS, Eppert K, Burrow SR, et al. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 1999;18:783-8.
4. Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retino-blastoma gene in osteosarcomas. Cancer Res 1994;54:3042-8.
5. Miller CW, Aslo A, Won A, et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 1996;122:559-65.
6. Kruzelock RP, Murphy EC, Strong LC, et al. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res 1997;57:106-9.
7. Yamaguchi T, Toguchida J, Yamamuro T, et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p and 18q. Cancer Res 1992;52: 2419-23.
8. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 1996;14:467-72.
9. Patiño A, Sotillo E, Sierrasesúmaga L. P21WAF1 mutation is not a predominant alteration in pediatric bone tumors. Pediatr Res 1998;43:393-5.
10. Miller CW. Aslo CA, Campbell MJ, et al. Alterations of p15, p16 and p18 genes in osteosarcoma. Cancer Genet Cytogenet 1996;86:136-42.
11. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
12. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10:5-15.
13. Patiño-García A, Sierrasesúmaga L. Analysis of the p16INK4 and p53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet 1997;98:50-5.
14. Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
15. Simpson DJ, Hibberts NA, McNicol AM, et al. Loss of pRB expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000;60:1211-6.
16. Shin J-Y, Kim H-S, Park J, et al. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res 2000;60:262-5.
17. Goto A, Kanda H, Ishikawa Y, et al. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res 1998;89: 539-47.
18. Lonardo F, Ueda T, Huvos AG, et al. P53 and MDM2 alterations in osteosarcomas: correlation with clinicopathological features and proliferative rate. Cancer 1997;79:1541-7.
19. Ladanyi M, Cha C, Lewis R, et al. MDM2 amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8.
20. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994;12: 925-30.
21. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 among patients with sarcoma. N Engl J Med 1992;326:1301-8.
22. Panizo C, Patiño A, Calasanz MJ, et al. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutation. Med Pediatr Oncol 1998;30:165-9.
23. Hudson M, Jaffe MR, Jaffe N. et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 1990;8:1988-97.
24. Bacci G, Ferrari S, Bertoni F, et al. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop 2001;386: 186-96.
25. Bacci B, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998;16:658-63.
26. Hauben E.I., Weeden S, Pringle J, et al. Does the histological subtype of highgrade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002:38:1218-25.